Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial

Vaccine

Volumn 29, Issue 8, 2011, Pages 1569-1575

  Plennevaux, Eric ^a   Blatter, Mark ^b   Cornish, Matthew J ^c   Go, Kerry ^a   Kirby, Daniel ^a   Wali, Mostafa ^a   Reeves Hoché, Mary Kate ^a   Denis, Martine ^a  

^a SANOFI PASTEUR   (France)

^b Primary Physicians Research   (United States)

^c Utah Valley Pediatrics   (United States)

Author keywords

Children; Clinical trial; H1N1; Pandemic influenza; Vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO;

ANTIBODY RESPONSE; ANTIBODY TITER; APPETITE DISORDER; ARTICLE; CHILD; DROWSINESS; DRUG SAFETY; ECCHYMOSIS; FEMALE; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; VOMITING;

EID: 79952698089     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.116     Document Type: Article

References (23)

1. World Health Organization. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009;84(25):249-60.
2. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009;361(27):2591-4.
3. Gomez J, Munayco C, Arrasco J, Suarez L, Laguna-Torres V, Aguilar P, et al. Pandemic influenzain a southern hemisphere setting: the experiencein Peru from May to September, 2009. Euro Surveill 2009;14.(42).
4. Update: influenza activity -United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009;58(36):1009-12.
5. World Health Organization. WHO. Pandemic (H1N1) 2009 - update 76. World Health Organization. 30-11-2009.
6. Update: influenza activity - United States, August 30-October 31, 2009. MMWR Morb Mortal Wkly Rep 2009;58(44):1236-41.
7. Finelli L, Brammer L, Kniss K, et al. Influenza epidemiology and surveillance. US Centers for Disease Control and Prevention; 2010, 3-11-2010.
8. O'Riordan S, Barton M, Yau Y, Read SE, Allen U, Tran D. Riskfactors andoutcomes among children admitted to hospital with pandemic H1N1 influenza. CMAJ 2009;182(1):39-44.
9. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory CommitteeonImmunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-10):1-8.
10. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2009;375(9708):41-8.
11. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-08):1-52.
12. World Health Organization.WHO manual on animal diagnosis and surveillance. World Health Organization; 2009, 21-11-2009.
13. CBER/FDA. Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines. United States Food and Drug Administration; 2009, 30-9-2009.
14. Liang XF, Wang HQ, Wang JZ, Fang H-H, Wu J, Zhu F-C, etal. Safety andimmuno-genicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56-66.
15. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang X-F, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361(25):2414-23.
16. Nolan T,McVernon J, Skeljo M,Richmond P,Wadia U,Lambert S, etal. Immuno-genicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010;303(1):37-46.
17. Carmona A, Omenaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. ImmunogenicityandsafetyofAS03-adjuvanted2009influenzaAH1N1 vaccine in children 6-35 months. Vaccine 2010;28(36):5837-44.
18. Oh CE, Lee J, Kang JH, Hong Y-J, Kim Y-K, Cheong H-J, et al. Safety and immuno-genicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multicenter trial. Vaccine 2010;28(36):5857-63.
19. Lu CY, Shao PL, Chang LY, Huang Y-C, Chiu C-H, Hsieh Y-C, etal. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 2010;28(36):5864-70.
20. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010;362(4):370-2.
21. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340:c2649.
22. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375(9720):1100-8.
23. Pedroza A, Huerta JG, Garcia ML, Rojas A, López-Martínez I, Penagos M, et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. Int J Infect Dis 2009;13(4):469-75.